Atyr PHARMA (NASDAQ:ATYR) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report sent to investors on Monday, Benzinga reports. They currently have a $35.00 price target on the stock.

Atyr PHARMA Stock Performance

Atyr PHARMA stock opened at $2.23 on Monday. Atyr PHARMA has a 1-year low of $1.08 and a 1-year high of $2.50. The company has a market capitalization of $153.89 million, a P/E ratio of -2.48 and a beta of 1.25. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02.

Insider Activity at Atyr PHARMA

In related news, Director Paul Schimmel bought 41,052 shares of the stock in a transaction on Monday, July 22nd. The shares were purchased at an average price of $1.74 per share, for a total transaction of $71,430.48. Following the acquisition, the director now owns 354,075 shares in the company, valued at $616,090.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is owned by corporate insiders.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.